Benzinga - 2025-05-13 11:30
Alzamend Neuro, Inc. (NASDAQ:ALZN) on Tuesday announced the initiation of the first of five Phase 2 clinical studies of AL001, with the first study in healthy human subjects. This study follows the development of a novel head coil by Tesla Dynamic Coils BV, a key component of the clinical trial. In collaboration with Massachusetts General Hospital as its clinical trial site, Alzamend aims to explore AL001 and its potential to deliver lithium more effectively in the brain than marketed lithium sa